한글목차

호흡기세포 융합 바이러스(RSV) 백신 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 13억 7,859만 달러에서 2026년에는 14억 8,218만 달러에 이르고, CAGR 7.5%로 성장할 전망입니다. 지난 몇 년간 RSV 관련 입원 환자 증가, 영유아 예방접종에 대한 미충족 수요, 호흡기 바이러스 감염에 대한 인식 개선, 계절성 RSV 유행에 대한 공중보건 감시, 임상시험 활동 확대 등이 성장의 원인으로 꼽힙니다.

호흡기세포 융합 바이러스(RSV) 백신 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 19억 5,768만 달러에 이르고, CAGR은 7.2%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 신규 RSV 백신 승인 증가, 정부의 예방접종 자금 지원 확대, 고령층 접종률 증가, 헬스케어 프로그램 확대, 복합백신 개발 집중 강화 등을 꼽을 수 있습니다. 주요 동향으로는 고위험군 대상 RSV 백신 개발 증가, 소아 및 노인 대상 예방접종 프로그램 강화, 첨단 백신 제제에 대한 투자 확대, 병원 기반 예방접종 캠페인 확대, 장기적인 RSV 예방에 대한 집중 등이 예상됩니다.

호흡기 감염증의 발생률 증가는 향후 호흡기세포 융합 바이러스(RSV) 백신 시장의 확대를 촉진할 것으로 예측됩니다. 바이러스, 세균, 기타 병원균에 의한 호흡기 감염은 부비동, 인후, 기도, 폐 등 호흡기 계통에 영향을 미칩니다. 호흡기 감염증 증가 추세는 대기오염, 기후 변화, 도시화, 고령화, 약제 내성 병원체 증가 등의 요인에 의해 영향을 받고 있습니다. RSV 백신은 RSV 관련 질환을 예방함으로써 호흡기 감염, 특히 영유아 및 노약자 등 취약 계층의 호흡기 감염 발생을 감소시키는 데 도움이 됩니다. 예를 들어, 2024년 10월 영국 정부 기관인 영국 보건안전청이 발표한 바에 따르면, 2023년 영국 내 결핵(TB) 발병 건수는 전년 대비 10.7% 증가하여 2022년 4,380건에서 4,850건으로 늘어났습니다고 합니다. 이에 따라 호흡기 감염증 증가 추세는 RSV 백신 시장의 성장에 기여할 것으로 예측됩니다.

RSV 백신 시장의 주요 기업들은 RSV 관련 합병증 위험이 높은 노년층에 대한 고효능 백신, 강화된 면역 보호 및 보다 안전한 제형에 대한 수요 증가에 대응하기 위해 재조합 단백질 기반 백신 기술과 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 재조합 단백질 기반 백신은 바이러스성분을 모방한 유전자 재조합 단백질을 사용하여 제조되며, 생바이러스를 사용하지 않고도 강력하고 표적화된 면역반응을 가능하게 합니다. 이는 기존 백신 방식에 비해 보다 통제되고 안정적인 대안을 제공합니다. 예를 들어, 2023년 5월 영국에 본사를 둔 제약회사 글락소 스미스클라인(GlaxoSmithKline)은 60세 이상의 개인에서 RSV로 인한 하기도 질환을 예방하기 위한 최초의 RSV 백신 '알렉스비'에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 알렉스비는 감염에 필수적인 주요 바이러스성분인 RSV 융합(F) 단백질을 표적으로 하는 첨단 재조합 단백질 기술을 채택하여 노인에게 강력한 보호 효과를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

영문목차

A respiratory syncytial virus (RSV) vaccine is a medical preparation aimed at protecting individuals, especially infants, older adults, and high-risk groups, from severe respiratory infections caused by RSV. It works by stimulating the immune system to recognize and combat the virus, thereby reducing the likelihood of hospitalization and severe illness.

The main types of RSV vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is specifically designed to prevent infections caused by viruses. These vaccines have various indications, including pediatric, geriatric, and high-risk populations, and are distributed through hospitals, pharmacies, and government suppliers.

Tariffs are impacting the respiratory syncytial virus vaccine market by increasing costs of imported biologic raw materials, adjuvants, specialized packaging components, and cold-chain storage equipment required for vaccine production and distribution. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on globally sourced inputs, while Asia-Pacific faces cost pressures on export-oriented vaccine manufacturing. These tariffs are increasing production expenses and affecting pricing strategies for public immunization programs. However, they are also encouraging localized vaccine manufacturing, regional supply chain strengthening, and long-term investments in domestic biopharmaceutical infrastructure.

The respiratory syncytial virus vaccine market research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus vaccine market statistics, including respiratory syncytial virus vaccine industry global market size, regional shares, competitors with a respiratory syncytial virus vaccine market share, detailed respiratory syncytial virus vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus vaccine industry. This respiratory syncytial virus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory syncytial virus vaccine market size has grown strongly in recent years. It will grow from $1378.59 million in 2025 to $1482.18 million in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising incidence of rsv-related hospitalizations, unmet medical need in infant immunization, increased awareness of respiratory viral infections, public health surveillance of seasonal rsv outbreaks, expansion of clinical trial activity.

The respiratory syncytial virus vaccine market size is expected to see strong growth in the next few years. It will grow to $1957.68 million in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing approval of novel rsv vaccines, growing government immunization funding, rising adoption among elderly populations, expansion of preventive healthcare programs, increasing focus on combination vaccine development. Major trends in the forecast period include increasing development of rsv vaccines for high-risk populations, rising focus on pediatric and geriatric immunization programs, growing investment in advanced vaccine formulations, expansion of hospital-based vaccination campaigns, enhanced emphasis on long-term rsv prevention.

The growing incidence of respiratory infections is expected to drive the expansion of the respiratory syncytial virus (RSV) vaccine market in the future. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the respiratory system, including the sinuses, throat, airways, or lungs. The increasing incidence of respiratory infections is influenced by factors such as air pollution, climate change, urbanization, aging populations, and the rise of drug-resistant pathogens. The RSV vaccine helps reduce the occurrence of respiratory infections by preventing RSV-related illnesses, particularly in vulnerable populations such as infants and older adults. For example, in October 2024, the UK Health Security Agency, a UK-based government body, reported a 10.7% year-over-year increase in tuberculosis (TB) cases in England in 2023, with cases rising from 4,380 in 2022 to 4,850. As a result, the growing incidence of respiratory infections will contribute to the growth of the RSV vaccine market.

Leading companies in the RSV vaccine market are focusing on developing innovative solutions, such as recombinant protein-based vaccine technologies, to meet the increasing demand for high-efficacy vaccines, improved immune protection, and safer formulations for older adults who are at greater risk of RSV-related complications. Recombinant protein-based vaccines are made using genetically engineered proteins that replicate viral components, enabling strong, targeted immune responses without the need for live viruses. This offers a more controlled and stable alternative to traditional vaccine approaches. For instance, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, received FDA approval for Arexvy, the first RSV vaccine aimed at preventing lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy uses advanced recombinant protein technology to target the RSV fusion (F) protein, a key viral component necessary for infection, offering robust protection for older adults.

In February 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for $1.1 billion. This acquisition strengthens AstraZeneca's vaccines and immune therapies pipeline, with Icosavax's lead candidate, IVX-A12, targeting RSV and human metapneumovirus (hMPV), two key pathogens responsible for severe respiratory infections in high-risk groups, including the elderly and individuals with chronic conditions. Icosavax, Inc. is a US-based clinical-stage biopharmaceutical company actively developing an RSV vaccine through its lead candidate, IVX-A12.

Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, Moderna Inc.

North America was the largest region in the respiratory syncytial virus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the respiratory syncytial virus vaccine market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The respiratory syncytial virus vaccine market consists of sales of protein-based vaccines, mRNA vaccines, monoclonal antibodies, and live-attenuated vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Syncytial Virus Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses respiratory syncytial virus vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory syncytial virus vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The respiratory syncytial virus vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
• 2) By Clinical Indications: Pediatric Indication; Geriatric Indication; High-Risk Individuals
• 3) By Distribution Channel: Hospital And Others Pharmacies; Government Suppliers
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Moderna Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Respiratory Syncytial Virus Vaccine Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Respiratory Syncytial Virus Vaccine Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Respiratory Syncytial Virus Vaccine Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Respiratory Syncytial Virus Vaccine Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Development Of Rsv Vaccines For High-Risk Populations
  • 4.2.2 Rising Focus On Pediatric And Geriatric Immunization Programs
  • 4.2.3 Growing Investment In Advanced Vaccine Formulations
  • 4.2.4 Expansion Of Hospital-Based Vaccination Campaigns
  • 4.2.5 Enhanced Emphasis On Long-Term Rsv Prevention

5. Respiratory Syncytial Virus Vaccine Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Pediatric Clinics
• 5.3 Geriatric Care Centers
• 5.4 Government Immunization Programs
• 5.5 Specialty Infectious Disease Clinics

6. Respiratory Syncytial Virus Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Respiratory Syncytial Virus Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Respiratory Syncytial Virus Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Respiratory Syncytial Virus Vaccine Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Respiratory Syncytial Virus Vaccine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Respiratory Syncytial Virus Vaccine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Respiratory Syncytial Virus Vaccine Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Respiratory Syncytial Virus Vaccine Market Segmentation

• 9.1. Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Viral Vaccine, Bacterial Vaccine, Combination Vaccine
• 9.2. Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatric Indication, Geriatric Indication, High-Risk Individuals
• 9.3. Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Government Suppliers

10. Respiratory Syncytial Virus Vaccine Market Regional And Country Analysis

• 10.1. Global Respiratory Syncytial Virus Vaccine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Respiratory Syncytial Virus Vaccine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Respiratory Syncytial Virus Vaccine Market

• 11.1. Asia-Pacific Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Respiratory Syncytial Virus Vaccine Market

• 12.1. China Respiratory Syncytial Virus Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Respiratory Syncytial Virus Vaccine Market

• 13.1. India Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Respiratory Syncytial Virus Vaccine Market

• 14.1. Japan Respiratory Syncytial Virus Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Respiratory Syncytial Virus Vaccine Market

• 15.1. Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Respiratory Syncytial Virus Vaccine Market

• 16.1. South Korea Respiratory Syncytial Virus Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 16.2. South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Respiratory Syncytial Virus Vaccine Market

• 17.1. Western Europe Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Respiratory Syncytial Virus Vaccine Market

• 18.1. UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Respiratory Syncytial Virus Vaccine Market

• 19.1. Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Respiratory Syncytial Virus Vaccine Market

• 20.1. France Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Respiratory Syncytial Virus Vaccine Market

• 21.1. Eastern Europe Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 21.2. Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Respiratory Syncytial Virus Vaccine Market

• 22.1. North America Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 22.2. North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Respiratory Syncytial Virus Vaccine Market

• 23.1. USA Respiratory Syncytial Virus Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 23.2. USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Respiratory Syncytial Virus Vaccine Market

• 24.1. Canada Respiratory Syncytial Virus Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 24.2. Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Respiratory Syncytial Virus Vaccine Market

• 25.1. South America Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 25.2. South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Respiratory Syncytial Virus Vaccine Market

• 26.1. Middle East Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Respiratory Syncytial Virus Vaccine Market

• 27.1. Africa Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 27.2. Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Segmentation By Clinical Indications, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Respiratory Syncytial Virus Vaccine Market Regulatory and Investment Landscape

29. Respiratory Syncytial Virus Vaccine Market Competitive Landscape And Company Profiles

• 29.1. Respiratory Syncytial Virus Vaccine Market Competitive Landscape And Market Share 2024
  • 29.1.1. Top 10 Companies (Ranked by revenue/share)
• 29.2. Respiratory Syncytial Virus Vaccine Market - Company Scoring Matrix
  • 29.2.1. Market Revenues
  • 29.2.2. Product Innovation Score
  • 29.2.3. Brand Recognition
• 29.3. Respiratory Syncytial Virus Vaccine Market Company Profiles
  • 29.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 29.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 29.3.3. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

30. Global Respiratory Syncytial Virus Vaccine Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Respiratory Syncytial Virus Vaccine Market

32. Respiratory Syncytial Virus Vaccine Market High Potential Countries, Segments and Strategies

• 32.1 Respiratory Syncytial Virus Vaccine Market In 2030 - Countries Offering Most New Opportunities
• 32.2 Respiratory Syncytial Virus Vaccine Market In 2030 - Segments Offering Most New Opportunities
• 32.3 Respiratory Syncytial Virus Vaccine Market In 2030 - Growth Strategies
  • 32.3.1 Market Trend Based Strategies
  • 32.3.2 Competitor Strategies

33. Appendix

• 33.1. Abbreviations
• 33.2. Currencies
• 33.3. Historic And Forecast Inflation Rates
• 33.4. Research Inquiries
• 33.5. The Business Research Company
• 33.6. Copyright And Disclaimer